A new iteration of the CONSORT statement has been unveiled, aiming to elevate the quality and transparency of randomized trial reporting. The updated CONSORT 2025 integrates recent methodological advancements and feedback from a diverse group of end users, ensuring that clinical research remains robust and reliable.
Comprehensive Revisions Introduced
Following an extensive scoping review and the creation of a specialized database, the CONSORT 2025 checklist underwent significant modifications. Seven new items were added, three existing items were revised, and one item was removed. Additionally, several elements from key CONSORT extensions were incorporated to provide a more holistic framework for trial reporting.
International Consensus Achieved
The development process involved a rigorous three-round Delphi survey with 317 participants and a two-day online consensus meeting with 30 international experts. This collaborative effort ensured that the updated guidelines reflect a wide range of perspectives and expertise, making them applicable across various research contexts.
Key Inferences:
- The integration of a new open science section underscores the importance of transparency in research practices.
- The expanded checklist facilitates more detailed and comprehensive reporting, reducing ambiguity in trial outcomes.
- Adoption of CONSORT 2025 is expected to enhance the reproducibility and credibility of randomized trials globally.
The revised CONSORT 2025 statement features a 30-item checklist essential for reporting randomized trials, alongside a participant flow diagram. An expanded version of the checklist offers bullet points detailing critical elements for each item, aiding authors in meticulous manuscript preparation.
Emphasizing clarity and transparency, the updated guidelines serve as a crucial tool for authors, editors, and reviewers. By adhering to CONSORT 2025, stakeholders can ensure that trial reports meet high standards of quality, facilitating better-informed healthcare decisions.
Adopting the CONSORT 2025 guidelines represents a significant step towards enhancing the integrity of clinical research. Researchers are encouraged to incorporate these standards early in the study design phase, which will streamline the reporting process and improve the overall impact of their findings. Additionally, training programs and workshops on the new checklist can support widespread implementation, fostering a culture of excellence in trial reporting.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
